Agenus Inc. AGEN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2000 · data as of November 13, 2026
Agenus Inc. (AGEN) is a healthcare company listed in the US with a market value of about $305M. In the twelve months to September 30, 2026 it had revenue of $134M and net income of $31M, a net margin of 23.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 29.3, 5-year revenue growth of 5% a year, a 5-year average ROIC of -402%.
About Agenus
Agenus is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2000. Revenue went from $7M in 2014 to $114M in 2025, growth of about 28.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 111% over three years (dilution for shareholders). It spends 69% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $134M | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M |
| Net income | $31M | -$101000 | -$227M | -$246M | -$220M | -$24M | -$181M | -$108M | -$162M | -$121M | -$127M |
| Free cash flow | -$104M | -$77M | -$159M | -$234M | -$228M | -$24M | -$143M | -$23M | -$135M | -$97M | -$92M |
| EPS (diluted) | $0.23 | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.00 | $-0.02 | $-0.02 | $-0.03 | $-0.02 | $-29.20 |
| Net margin | 23.0% | -0.1% | -219.8% | -157.4% | -224.7% | -8.2% | -205.4% | -71.9% | -440.5% | -281.5% | -562.6% |
| ROIC | — | — | — | — | -826.5% | 21.9% | — | — | — | -119.0% | -117.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $27.00, 301% above the current price; targets range from $16.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $0.82 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Agenus’s P/E ratio?
About 29.3, based on the last twelve months of diluted earnings per share.
Does Agenus pay a dividend?
Not currently.
Is Agenus a good stock to buy?
We do not give buy or sell advice. Agenus scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.